TGFB1 and renal fibrosis: In liver and renal fibrosis, current therapies mostly focus on metabolic and immune-mediated pathways [40,44,46], whereas cardiac fibrosis research is intensifying around TGFβ blockade [61,62], modulation of myofibroblast mechanotransduction, and antiremodeling strategies.